Kazia has launched a new Scientific Advisory Board (SAB) consisting of four distinguished clinicians and scientists with expertise in the development of innovative therapies for brain cancer.

Kazia has been awarded a Rare Paediatric Disease Designation (RPDD) by the US Food and Drug Administration (FDA) for the use of paxalisib in the treatment of atypical rhabdoid/teratoid tumours (AT/RT), a rare and highly aggressive childhood brain cancer.

The US FDA has awarded Kazia Therapeutics (ASX:KZA) a designation for its treatment for rare brain cancer in children.